Merck & Co., Inc. (MRK)
NYSE: MRK · Real-Time Price · USD
111.01
+2.75 (2.54%)
At close: Jan 14, 2026, 4:00 PM EST
110.60
-0.41 (-0.37%)
Pre-market: Jan 15, 2026, 6:14 AM EST
Merck & Co. Employees
As of December 31, 2024, Merck & Co. had 75,000 total employees, including 73,000 full-time and 2,000 part-time employees. The number of employees increased by 3,000 or 4.17% compared to the previous year.
Employees
75,000
Change (1Y)
3,000
Growth (1Y)
4.17%
Revenue / Employee
$856,467
Profits / Employee
$253,787
Market Cap
275.53B
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 75,000 | 3,000 | 4.17% |
| Dec 31, 2023 | 72,000 | 3,000 | 4.35% |
| Dec 31, 2022 | 69,000 | 1,000 | 1.47% |
| Dec 31, 2021 | 68,000 | -6,000 | -8.11% |
| Dec 31, 2020 | 74,000 | 3,000 | 4.23% |
| Dec 31, 2019 | 71,000 | 2,000 | 2.90% |
| Dec 31, 2018 | 69,000 | 0 | - |
| Dec 31, 2017 | 69,000 | 1,000 | 1.47% |
| Dec 31, 2016 | 68,000 | 0 | - |
| Dec 31, 2015 | 68,000 | -2,000 | -2.86% |
| Dec 31, 2014 | 70,000 | -6,000 | -7.89% |
| Dec 31, 2013 | 76,000 | -7,000 | -8.43% |
| Dec 31, 2012 | 83,000 | -3,000 | -3.49% |
| Dec 31, 2011 | 86,000 | -8,000 | -8.51% |
| Dec 31, 2010 | 94,000 | -6,000 | -6.00% |
| Dec 31, 2009 | 100,000 | - | - |
Sources: Annual number of employees according to filings submitted to the U.S. Securities and Exchange Commission (SEC). Data is also manually gathered from company press releases, IPO filings, and other official sources.
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Thermo Fisher Scientific | 125,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 92,900 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| AbbVie | 55,000 |
MRK News
- 2 days ago - Merck & Co., Inc. (MRK) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript - Seeking Alpha
- 2 days ago - Merck says new growth opportunities to drive revenue of $70 billion by mid-2030s - Reuters
- 3 days ago - The 2026 Dogs Of The Dow: 10 High-Yield Blue Chips - Forbes
- 4 days ago - January Dogs Of The Dow: One Ideal 'Safer' Dividend Buy - Seeking Alpha
- 5 days ago - Merck is in talks to acquire Revolution Medicines in a deal that could value the cancer-drug biotech at around $30 billion - WSJ
- 5 days ago - Healthy Returns: What to expect from pharma at the JPM conference - CNBC
- 6 days ago - Merck urges science-led US vaccine schedule after CDC trims childhood vaccine list - Reuters
- 6 days ago - Merck in talks to buy biotech Revolution Medicines, FT reports - Reuters